Achieving hepatitis B surface antigen seroclearance neutralizes the increased risk for hepatitis B virus-related hepatocellular carcinoma among women aged 50 years or younger, but not among older women or men regardless of their age, research indicates.
Achieving a subcirrhotic liver stiffness level after antiviral therapy halves the risk for hepatocellular carcinoma in patients with chronic hepatitis B virus-related advanced fibrosis or cirrhosis, Korean research shows.
The Japanese nationwide selective vaccination strategy has led to a substantial reduction in perinatal hepatitis B virus transmission, say researchers who evaluated the prevalence of hepatitis B surface antigen among pregnant women born before and after its implementation.
A high burden of metabolic risk factors significantly increases the risk for hepatocellular carcinoma among men with hepatitis B virus infection, particularly those who smoke, researchers from Taiwan report.
In patients with persistently low serum levels of hepatitis B virus DNA, the combined use of the noninvasive aspartate aminotransferase to platelet ratio index and the Fibrosis-4 index could help identify those at increased risk for developing hepatocellular carcinoma.
The incidence of hepatocellular carcinoma in patients with chronic hepatitis B virus infection declines significantly after the first 5 years of treatment with the nucleos(t)ide analogs entecavir and/or tenofovir, researchers report.
Analysis of a community-based cohort comprising mainly Asian patients receiving antiviral therapy for chronic hepatitis B virus infection shows a higher rate of hepatitis B surface antigen loss than is generally reported for Asian clinical trial cohorts.
Serum hepatitis B core antibody levels significantly predict hepatic inflammation in patients with chronic hepatitis B virus infection, including those with normal alanine aminotransferase levels, Chinese research shows.
A South Korean population-based study shows an increase in liver cancer burden over a 14-year period, while another analysis in the same population shows an improvement in the survival of patients with hepatocellular cancer in the past decade.
Despite a universal program to vaccinate newborns against hepatitis B virus infection, the prevalence of overt and occult infection among children in northwest China is a cause for concern, say researchers.
Among patients with hepatitis B virus-related decompensated cirrhosis, first-line tenofovir disoproxil fumarate therapy not only reduces HBV DNA levels, but also improves hepatic function, indicates a real-world South Korean study.
The infant recombinant yeast hepatitis B virus vaccine has long-term efficacy, but the rate of disappearance of protective antibodies against hepatitis B surface antigen is higher than with the plasma-derived vaccine, shows a study of Taiwanese university students.
Korean researchers show that the PAGE-B model for prediction of hepatocellular carcinoma risk has applicability in Asian patients with chronic hepatitis B virus infection treated with entecavir or tenofovir disoproxil fumarate.
Treatment with tenofovir disoproxil fumarate alone is efficacious over the long term in patients with chronic hepatitis B virus infection that is resistant to multiple antiviral agents, research indicates.
Serial liver stiffness measurement is a useful tool for monitoring longitudinal improvements in advanced fibrosis among patients receiving antiviral treatment for chronic hepatitis B virus infection, say researchers.
Long-term tenofovir disoproxil fumarate salvage therapy is effective for patients with chronic hepatitis B virus infection who have previously failed to respond to lamivudine and adefovir dipivoxil, 5-year TDF-109 study data show.
Treatment with a tenofovir disoproxil fumarate-containing regimen or entecavir leads to high virologic and biochemical response rates in patients with chronic hepatitis B virus infection, shows a registry analysis.
Hepatic steatosis, hepatitis B e antigen seropositivity, and age are independently associated with persistent increases in serum alanine aminotransferase levels in patients with chronic hepatitis B virus infection receiving antiviral therapy, a study shows.